Breast cancer patients await ruling on Herceptin
Thursday 08 June 2006
Long-awaited recommendations on which women should receive the breast cancer drug Herceptin are to be issued tomorrow.
Thousands of patients who could benefit from the treatment are hoping that the National Institute for Health and Clinical Excellence (Nice) will say all those with suitable early-stage breast cancer should be entitled to receive it on prescription.
But there are concerns that NHS trusts, which are already struggling with multimillion-pound deficits, will continue to restrict access to the drug, which costs £20,000 a year per patient. The Government says there will be no extra money to fund the Nice guidance on Herceptin and the cost must be found from existing budgets.
Dr Gill Morgan, chief executive of the NHS Confederation, said: "Without doubt, this will present a significant financial challenge to some organisations. The problem is that organisations have to plan their expenditure 18 months in advance and so when a drug is fast-tracked through the process - as this drug has been -it causes several difficulties.
"Trusts don't want to put too much money aside in case they end up in surplus with funds that could have gone to patient care but they have to make a guess because if they end up in deficit it is as bad and some other service has to be cut."
Roche, the maker of Herceptin, was granted a licence for its use in treating early-stage breast cancer by the European Medicines Agency last week.
The drug is already used in cases of advanced breast cancer but studies have shown that it can dramatically reduce the risk of the disease returning in women diagnosed at an earlier stage.
Women with early-stage disease have been forced to go to the High Court to seek the right to the treatment because NHS trusts have said the lack of a relevant licence meant they were under no obligation to provide it.
Under pressure from patients and ministers, Nice has fast-tracked assessment of the data on Herceptin for early breast cancer. More than 5,000 women a year diagnosed with early-stage, HER-2 positive breast cancer - an aggressive type - could benefit from Herceptin.
Life & Style blogs
Jennifer Lawrence nude pictures leaked: Reddit removes 'The Fappening' board dedicated to sharing naked pictures of celebrities
iPhone 'Wave': iOS 8 hoax claims you can charge your iPhone in the microwave - you can't
London Fashion Week Spring/Summer 2015: Distraction could not disguise a distinct lack of focus
A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
iOS 8 HealthKit catches a major bug, forcing Apple's fitness apps to lie down and take it easy
- 1 'The Fappening': Rihanna 'nude pictures' claims emerge on 4Chan as hacking scandal continues
- 2 Frank Lampard equalises for Manchester City against Chelsea: how the internet reacted
- 5 Hitler’s former food taster reveals the horrors of the Wolf’s Lair
£70000 - £80000 per annum: Ashdown Group: Group Head of Marketing and Communic...
Negotiable: Randstad Education Manchester: Level 3 Nursery Nurse required for ...
Negotiable: Randstad Education Manchester: L3 Nursery Nurses urgently required...
Negotiable: Randstad Education Manchester: We have a number of schools based S...